SCHEMBL2883618

SCHEMBL2883618

COc1ccc(CCn2cnc3ccc(C=C4SC(=O)NC4=O)cc32)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.58
PIM1 P11309 2/20 0.58
PIM3 Q86V86 2/20 0.58
PIM2 Q9P1W9 2/20 0.58
IGF1R P08069 1/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MGAM O43451 1/20 0.50
GAA P10253 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
HPGD P15428 6/20 0.49
GSK3B P49841 3/20 0.49
PDE3A Q14432 1/20 0.47
CDC7 O00311 1/20 0.47
DAPK3 O43293 1/20 0.47
DYRK3 O43781 1/20 0.47
MAP4K4 O95819 1/20 0.47
PHKG2 P15735 1/20 0.47
RPS6KB1 P23443 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883617 1.00 PDE4B (0.58) PDE4BPIM1PIM3PIM2IGF1R
SCHEMBL6422799 0.85 HPGD (0.52) PIM1PIM3PIM2IGF1RMGAM
SCHEMBL2877667 0.85 HPGD (0.52) PIM1PIM3PIM2IGF1RMGAM
SCHEMBL2877670 0.85 HPGD (0.52) PIM1PIM3PIM2IGF1RMGAM
SCHEMBL2882113 0.83 HPGD (0.56) MGAMGAASIMGAM2HPGD
SCHEMBL2882116 0.83 HPGD (0.56) MGAMGAASIMGAM2HPGD
SCHEMBL2882172 0.82 PIM1 (0.55) PIM1PIM2MGAMGAASI
SCHEMBL2882174 0.82 PIM1 (0.55) PIM1PIM2MGAMGAASI
SCHEMBL2883164 0.82 CISD1 (0.54) PDE4BPIM1PIM3PIM2IGF1R
SCHEMBL2883161 0.82 CISD1 (0.54) PDE4BPIM1PIM3PIM2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 US claimed
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia MERCK SERONO SA (CH) 2009-02-12 US claimed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 US claimed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 US claimed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 US disclosed
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2008-12-11 US disclosed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 US disclosed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX PDE4B 3295/4885PIM1 2247/4885PIM3 3234/4885
US-20090042773-A1 P13 kinase gamma inhibitors for the treatment of anaemia PDPK1, PRKD3, PRKD1 PDE4B 2130/4885PIM1 201/4885PIM3 91/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 PDE4B 33/4885PIM1 2811/4885PIM3 1803/4885
US-20080306057-A1 P13K Inhibitors for the Treatment of Endometriosis PDPK1, PIK3R4, MAP3K3 PDE4B 832/4885PIM1 864/4885PIM3 556/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B PDE4B 3338/4885PIM1 2412/4885PIM3 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.